Background
==========

B-type natriuretic peptide (BNP) is released from cardiac ventricles in response to increased wall tension \[[@B1]\]. Measurement of BNP is useful in establishing the diagnosis of heart failure \[[@B2]\]. N-terminal pro-B-type natriuretic peptide (NT-pro-BNP), a precursor of BNP, provides prognostic information superior to that obtained from BNP in patients with myocardial infarction \[[@B3]\]. NT-pro-BNP has been shown to be a good prognostic marker in patients with cardiac disease \[[@B4]\].

NT-pro-BNP levels are elevated not only in patients with cardiac disease but also in critically ill patients. Okkonen *et al*. \[[@B5]\] showed that the NT-pro-BNP level on patient admission is commonly elevated in patients with acute respiratory failure. Wang *et al*. \[[@B6]\] reported that elevated NT-pro-BNP levels may prove to be a powerful predictor of mortality in septic patients. NT-pro-BNP level may be a prognostic marker in critically ill patients \[[@B7]-[@B10]\]. However, few large-scale multicenter studies have assessed NT-pro-BNP as a prognostic factor. Also, little is known regarding the correlation between NT-pro-BNP and clinical parameters in critically ill patients. Moreover, it is not clear in which conditions NT-pro-BNP is elevated. Thus, by using a large cohort we aimed to assess the prognostic value of NT-pro-BNP level in patients admitted to the intensive care unit (ICU) and analyzed the relationship between the level of NT-pro-BNP and clinical parameters.

Methods
=======

We used data from the "Validation of simplified acute physiology score 3 in Korean ICUs" (VSKI) study cohort. VSKI was a prospective multicenter cohort study that aimed to validate the simplified acute physiology score (SAPS) 3 in Korean ICU patients that was performed by the Korean Study group on Respiratory Failure (KOSREF) between July 1st, 2010 and January 31st, 2011. VSKI included 22 ICUs (medical, 14; surgical, six; multidisciplinary, two) in 15 tertiary or university-affiliated hospitals. The study was approved by the institutional review board of the Seoul St. Mary's Hospital, Samsung Medical Center, Severance Hospital, Keimyung University Dongsan Hospital, Aju University Hospital, Konkuk University Chungju Hospital, Korea University Ansan Hospital, Armed Forces Capital Hospital, Chung-Ang University Hospital, Gangneung Asan Hospital, Hallym University Sacred Heart Hospital, Gyeongsang National University Hospital, Ewha Womans University Hospital, Bundang CHA Hospital and Asan Medical Center. The requirement for informed consent was waived because of the observational nature of the study.

Patients
--------

All patients admitted to the 22 ICUs during the study period were eligible for the present study. Patients whose NT-pro-BNP levels were measured on ICU admission were included in the study. We excluded patients who were younger than 17 years. Patients who were transferred from other participating ICUs were also excluded. For patients with two or more admissions to the ICU during the same hospital stay, only the data from the first admission were used. Patients whose ICU or hospital mortality was uncertain were excluded in the analysis.

Data collection
---------------

Patient data were recorded prospectively in a web-based database. We obtained data on demographic characteristics (age, gender, body weight, and height), underlying disease, SAPS 3, sequential organ failure assessment (SOFA) score, severe sepsis, or septic shock on ICU admission, acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) on ICU admission, admission category (medical or surgical), admission diagnosis, organ support (mechanical ventilation, renal replacement therapy, and use of vasopressors), length of ICU stay and hospital stay, and mortality on ICU and hospital discharge. The medical history of each patient was reviewed thoroughly, and the initial vital signs on ICU admission were recorded. Laboratory data, including complete blood cell count, chemistry, and arterial blood gas analysis were collected within 24 h of ICU admission. Illness severity was assessed using the SAPS 3 score. Blood NT-pro-BNP level was determined together with all SAPS 3 variables.

Data analysis
-------------

We compared the level of NT-pro-BNP on admission in patients with hospital survivors and nonsurvivors. Then, we compared the mortality rate according to the quintile of NT-pro-BNP. We also compared the level of NT-pro-BNP according to the reason of ICU admission and analyzed correlation between NT-pro-BNP and clinical parameters. We calculated prognostic power of NT-pro-BNP to predict mortality and compared with that of SAPS 3 score. Finally, we analyzed if there was additive benefit when combining NT-pro-BNP with SAPS 3 score.

Statistical analysis
--------------------

Because most of the data were not normally distributed, all results are presented as medians and interquartile ranges (IQRs), or as numbers (percentages) of patients. Differences between groups were assessed using chi-squared test or Fisher's exact test for categorical variables, as appropriate. For continuous variables, differences between two groups were assessed by the Mann--Whitney *U*-test and differences among four groups were assessed by the Kruskal--Wallis test. Correlations between continuous variables were assessed by Spearman's test. Receiver operating characteristic (ROC) curves were generated for NT-pro-BNP and SAPS 3. SAPS 3 and NT-pro-BNP were evaluated for their association with hospital survival by logistic regression analysis. NT-pro-BNP was transformed into a natural log (ln) scale because of the wide range of levels. All tests were two sided, and *P* values less than 0.05 were considered to indicate statistical significance. All statistical analyses were performed using PASW Statistics, version 17 (SPSS, Chicago, IL, USA).

Results
=======

NT-pro-BNP levels in 1,643 patients were measured upon ICU admission. Among them, ICU mortality data were available for 1,561 patients, and hospital mortality data were available in 1440 patients. Thus, 1440 patients were included in the study (Figure [1](#F1){ref-type="fig"}). The median age was 64 years (range, 53--73 years), and 906 (62.9%) were male. On ICU admission, 309 (21.5%) patients had severe sepsis or septic shock, and 123 (8.5%) were ALI or ARDS. The median NT-pro-BNP was 341 pg/mL (range, 104--1,637 pg/mL), and the median SAPS 3 score was 57 (range, 47--69). The ICU mortality rate was 18.9%, and the hospital mortality rate was 24.5%. The baseline characteristics of the patients are shown in Table [1](#T1){ref-type="table"}.

![Enrolled patients.](1471-2253-14-16-1){#F1}

###### 

Baseline characteristics of patients (n = 1440)

  **Characteristics**               **Median (IQR) or No. (%)**
  -------------------------------- -----------------------------
  Age in years (range)                      64 (53--73)
  Male                                      906 (62.9)
  Comorbidities                                   
   Cirrhosis                                157 (10.9)
   Hypertension                             544 (37.8)
   IHD                                      160 (11.1)
   CHF                                       108 (7.5)
   DM                                       363 (25.2)
   CRF                                      144 (10.0)
   Cancer                                   544 (37.8)
  Status at ICU admission                         
   Severe sepsis or septic shock            309 (21.5)
   ALI or ARDS                               123 (8.5)
  Admission category                              
   Medical                                  835 (58.0)
   Surgical                                 605 (42.0)
  Reason for ICU admission                        
   Basic & observational^\*\*^              583 (40.5)
   Cardiovascular                           264 (18.3)
   Digestive                                 62 (4.3)
   Hepatic failure                           86 (6.0)
   Neurologic                                35 (2.4)
   Renal                                     21 (1.5)
   Respiratory                              310 (21.5)
  NT-pro-BNP (pg/mL)                     341 (104--1,637)
  SAPS 3 score                              57 (47--69)
  SOFA score                                 7 (3--11)
  ICU day                                    7 (4--16)
  ICU mortality                             272 (18.9)
  Hospital day                              18 (10--35)
  Hospital mortality                        353 (24.5)

^\*\*^Basic and observational intensive care were defined as management of a patient in the ICU for surveillance, simple weaning from a ventilator after surgery, routine post-surgery care, or needing complex nursing care or monitoring of drug intoxication without organ dysfunction.

IQR = interquartile range; IHD = ischemic heart disease; CHF = congestive heart failure; DM = diabetes mellitus; CRF = chronic renal failure; ICU = intensive care unit; ALI = acute lung injury; ARDS = acute respiratory distress syndrome; SAPS 3 = Simplified Acute Physiology Score (SAPS) 3.

ICU survivors had significantly lower NT-pro-BNP values than ICU nonsurvivors (268 pg/mL \[range, 80--1,140 pg/mL\] *vs*. 1,021 pg/mL \[range, 232--6,256 pg/mL\], respectively; *p* \< 0.001). Likewise, hospital survivors were characterized by significantly lower NT-pro-BNP values than hospital nonsurvivors (245 pg/mL \[range, 82--1,053 pg/mL\] *vs*. 875 pg/mL \[range, 241--5,000 pg/mL\], respectively; *p* \< 0.001). Figure [2](#F2){ref-type="fig"} shows box and whisker plots for hospital survival.

![**Box and whisker plots for hospital survival.** The NT-pro-BNP level was significantly higher in nonsurvivors than survivors.](1471-2253-14-16-2){#F2}

The NT-pro-BNP level was significantly different according to the reason for ICU admission (*p* \< 0.001; Figure [3](#F3){ref-type="fig"}). The level of NT-pro-BNP was highest in patients whose reason for ICU admission was a renal complication (7,946 pg/mL \[range, 890--24,118 pg/mL\]), followed by a cardiovascular complication (1,154 pg/mL \[range, 190--5,217 pg/mL\]). The level of NT-pro-BNP was significantly different according to underlying disease or clinical situation (Table [2](#T2){ref-type="table"}). Significant correlations between NT-pro-BNP level and many clinical parameters were found (Table [3](#T3){ref-type="table"}).

![**Box and whisker plots for the reason for ICU admission.** NT-pro-BNP levels varied according to the reason for ICU admission.](1471-2253-14-16-3){#F3}

###### 

Level of NT-pro-BNP (pg/mL) according to the underlying disease or clinical situation

  **Variables**                         **No. (%)**     **Median (IQR)**     ***p*-value**
  ----------------------------------- --------------- --------------------- ---------------
  Female                                534 (37.1%)     420 (137--1,780)         0.008
  Male                                  906 (62.9%)      292 (84--1,520)    
  Cirrhosis (-)                        1,283 (89.1%)    385 (109--1,808)        \<0.001
  Cirrhosis (+)                         157 (10.9%)       187 (83--526)     
  Hypertension (-)                      896 (62.2%)      276 (86--1,208)        \<0.001
  Hypertension (+)                      544 (37.8%)     456 (125--2,384)    
  IHD (-)                              1,280 (88.9%)     296 (93--1,309)        \<0.001
  IHD (+)                               160 (11.1%)     967 (251--4,894)    
  CHF (-)                              1,332 (92.5%)     299 (93--1,382)        \<0.001
  CHF (+)                               108 (7.5%)     1,226 (413--8,346)   
  DM (-)                               1,077 (74.8%)     284 (94--1,223)        \<0.001
  DM (+)                                363 (25.2%)     611 (129--3,373)    
  CRF (-)                              1,296 (90.0%)     276 (91--1,127)        \<0.001
  CRF (+)                               144 (10.0%)    2,799 (773--16,768)  
  Cancer (-)                            896 (62.2%)     390 (101--2,214)         0.027
  Cancer (+)                            544 (37.8%)     285 (108--1,024)    
  Severe sepsis or septic shock (-)    1,131 (78.5%)     269 (85--1,112)        \<0.001
  Severe sepsis or septic shock (+)     309 (21.5%)     890 (206--7,946)    
  ALI or ARDS (-)                      1,317 (91.5%)    309 (100--1,389)        \<0.001
  ALI or ARDS (+)                       123 (8.5%)      827 (191--3,504)    
  Elective surgery                      502 (34.9%)       195 (78--492)         \<0.001
  Emergency surgery                     103 (7.2%)        233 (97--981)     
  Surgery (-)                           835 (58.0%)     604 (148--3,170)    
  MV (-)                                770 (53.5%)      264 (83--1,064)        \<0.001
  MV (+)                                670 (46.5%)     456 (129--2,542)    
  Vasoactive drug (-)                   904 (62.8%)       237 (79--828)         \<0.001
  Vasoactive drug (+)                   536 (37.2%)     721 (178--3,720)    
  RRT (-)                              1,268 (88.1%)    278 (93 -- 1,164)       \<0.001
  RRT (+)                               172 (11.9%)    2,377 (413--18,751)          

IQR = interquartile range; IHD = ischemic heart disease; CHF = congestive heart failure; DM = diabetes mellitus; CRF = chronic renal failure; ALI = acute lung injury; ARDS = acute respiratory distress syndrome; MV = mechanical ventilation; RRT = renal replacement therapy.

###### 

Correlations between NT-pro-BNP and clinical parameters

  **Clinical parameters**    **Correlation coefficient (p)**   ***p*-value**
  ------------------------- --------------------------------- ---------------
  Age                                     0.19                    \<0.001
  Lowest MAP                              -0.22                   \<0.001
  Highest HR                              0.25                    \<0.001
  Highest BT                              0.13                    \<0.001
  Lowest platelet                         -0.11                   \<0.001
  Highest total bilirubin                 -0.07                    0.006
  Highest BUN                             0.40                    \<0.001
  Highest Cr                              0.33                    \<0.001
  Lowest Na                               -0.12                   \<0.001
  Highest K                               0.14                    \<0.001
  Lowest pH                               -0.09                    0.001
  Lowest HCO~3~^-^                        -0.17                   \<0.001
  Lowest PaO~2~                           -0.25                   \<0.001
  Highest PaCO~2~                         -0.06                    0.029
  Highest GCS                             -0.10                   \<0.001
  Lowest PF ratio                         -0.26                   \<0.001
  Input                                   0.07                     0.013
  Urine output                            -0.11                   \<0.001

MAP = mean arterial pressure, HR = heart rate, BT = body temperature, BUN = blood urea nitrogen, Cr = creatinine, Na = sodium, K = potassium, GCS = Glasgow Coma Scale, PF ratio = PaO~2~/FIO~2~ ratio.

ROC curve analysis was used to identify the NT-pro-BNP level and SAPS 3 score on admission that best predicted hospital mortality. An NT-pro-BNP concentration of 514.8 pg/mL had a sensitivity of 62% and specificity of 66% for predicting hospital mortality. Positive predictive value was 0.37 and negative predictive value was 0.84. The area under the ROC curve was 0.67 (95% confidence interval \[CI\], 0.64--0.70). A SAPS 3 score of 60.5 had a sensitivity of 81% and specificity of 70% for predicting hospital mortality. The area under the ROC curve was 0.83 (95% CI, 0.81--0.85). AUC increment by adding NT-pro-BNP is minimal and likely no different to SAPS 3 alone (Table [4](#T4){ref-type="table"}, Figure [4](#F4){ref-type="fig"}).

###### 

The area under the ROC curve in prediction of hospital mortality

                                                   **AUC**   **95% CI**    ***p*-value**
  ----------------------------------------------- --------- ------------- ---------------
  NT-pro-BNP                                        0.671    0.639-0.704      \<0.001
  SAPS3                                             0.828    0.805-0.852      \<0.001
  SAPS3 + ln~NT-pro-BNP~ (continuous variable)      0.831    0.808-0.855      \<0.001
  SAPS3 + ln~NT-pro-BNP~ (categorical variable)     0.835    0.812-0.858      \<0.001

ROC = Receiver operating characteristic; AUC = area under the curve; CI = confidence interval; SAPS 3 = Simplified Acute Physiology Score (SAPS) 3.

Natural-log-transformed (ln) NT-pro-BNP was used as the continuous variable or divided by the quartile and used as the categorical variable.

![**Receiver operating characteristic (ROC) curve analysis for hospital mortality.** The area under the ROC curve was 0.67 for the NT-pro-BNP level and 0.83 for the SAPS 3 score. Combine of NT-pro-BNP level and SAPS 3 score resulted in little additional power.](1471-2253-14-16-4){#F4}

Almost all clinical characteristics differed significantly according to NT-pro-BNP level (Table [5](#T5){ref-type="table"}). The percentage of ischemic heart disease, congestive heart failure, and chronic renal failure were increased according to NT-pro-BNP level quartile. Among the reasons for ICU admission, the rates of cardiovascular and renal complications were increased according to the NT-pro-BNP level quartile. SAPS 3 score, SOFA score, ICU day, and ICU mortality also increased according to NT-pro-BNP level quartile. Hospital mortality also differed significantly according to NT-pro-BNP level (11.4% in the first quartile, 18.3% in the second quartile, 29.7% in the third quartile, and 38.6% in the fourth quartile; *p* \< 0.001; Figure [5](#F5){ref-type="fig"}).

###### 

Comparison of clinical characteristics according to the quartile of NT-pro-BNP level

  **NT-pro-BNP (pg/mL)**            **\< 104**    **104--341**   **341--1,637**   **\> 1,637**   ***p*-value**
  -------------------------------- ------------- -------------- ---------------- -------------- ---------------
  Number of patients                    360           360             360             360               
  Age, years                        59 (49--69)   63 (52--72)     67 (55--76)     68 (56--75)      \< 0.001
  Male                              250 (69.4)     223 (61.9)      213 (59.2)      220 (61.1)        0.024
  Comorbidities                                                                                         
   Cirrhosis                         47 (13.1)     62 (17.2)        29 (8.1)        19 (5.3)       \< 0.001
   Hypertension                     118 (32.8)     120 (33.3)      142 (39.4)      164 (45.6)        0.001
   IHD                               18 (5.0)       29 (8.1)       49 (13.6)       64 (17.8)       \< 0.001
   CHF                                5 (1.4)       18 (5.0)       37 (10.3)       48 (13.3)       \< 0.001
   DM                                75 (20.8)     71 (19.7)       94 (26.1)       123 (34.2)      \< 0.001
   CRF                                8 (2.2)       16 (4.4)        35 (9.7)       85 (23.6)       \< 0.001
   Cancer                           130 (36.1)     164 (45.6)      144 (40.0)      106 (29.4)      \< 0.001
  Status at ICU admission                                                                               
   Severe sepsis or septic shock     42 (11.7)     64 (17.8)       75 (20.8)       128 (35.6)      \< 0.001
   ALI or ARDS                       18 (5.0)       27 (7.5)        28 (7.8)       50 (13.9)       \< 0.001
  Admission category                                                                                    
   Medical                          171 (47.5)     159 (44.2)      212 (58.9)      293 (81.4)      \< 0.001
   Surgical                         189 (52.5)     201 (55.8)      148 (41.1)      67 (18.6)       \< 0.001
  Reason for ICU admission                                                                              
   Basic & observational^\*\*^      166 (46.1)     174 (48.3)      156 (43.3)      87 (24.2)       \< 0.001
   Cardiovascular                    40 (11.1)     47 (13.1)       58 (16.1)       119 (33.1)      \< 0.001
   Digestive                         22 (6.1)       14 (3.9)        15 (4.2)        11 (3.1)         0.236
   Hepatic failure                   29 (8.1)      39 (10.8)        14 (3.9)        4 (1.1)        \< 0.001
   Neurologic                        10 (2.8)       5 (1.4)         9 (2.5)         11 (3.1)         0.519
   Renal                              1 (0.3)       2 (0.6)         3 (0.8)         15 (4.2)       \< 0.001
   Respiratory                       61 (19.6)     66 (18.3)       90 (25.0)       93 (25.8)         0.004
  SAPS 3 score                      50 (39--61)   55 (47--65)     58 (49--68)     68 (57--78)      \< 0.001
  SOFA score                         5 (2--9)      6 (3--10)       6 (3--11)       10 (6--13)      \< 0.001
  ICU day                            5 (3--12)     6 (4--16)       7 (4--17)       9 (4--20)       \< 0.001
  ICU mortality                      28 (7.8)      55 (15.3)       76 (21.1)       113 (31.4)      \< 0.001
  Hospital day                      16 (9--31)    17 (11--35)     17 (11--37)     19 (10--38)        0.106
  Hospital mortality                 41 (11.4)     66 (18.3)       107 (29.7)      139 (38.6)      \< 0.001

^\*\*^Basic and observational intensive care was defined as the patient being in the ICU for surveillance, simple weaning from a ventilator after surgery, routine post-surgery care, or needing complex nursing care or monitoring drug intoxication without organ dysfunction.

IHD = ischemic heart disease; CHF = congestive heart failure; CPF = chronic pulmonary disease; DM = diabetes mellitus; CRF = chronic renal failure; ICU = intensive care unit; ALI = acute lung injury; ARDS = acute respiratory distress syndrome.

![**Hospital mortality according to NT-pro-BNP level.** Mortality increased with the quartile of the NT-pro-BNP level.](1471-2253-14-16-5){#F5}

Logistic regression was performed to determine whether the NT-pro-BNP level has additional power to predict hospital mortality in combination with the SAPS 3 score. The odds ratio of the SAPS 3 score alone was 1.10. When combined with NT-pro-BNP, the odds ratio of the SAPS 3 score was 1.09 (Tables [6](#T6){ref-type="table"} and [7](#T7){ref-type="table"}). There was little change in the odds ratio and 95% CI of SAPS 3 when combined with NT-pro-BNP.

###### 

Logistic regression for prediction of hospital mortality (SAPS 3 alone)

                  **Odds ratio**   **95% CI**   ***p*-value**
  -------------- ---------------- ------------ ---------------
  SAPS 3 score         1.10        1.08-1.10      \< 0.001

Goodness of fit (Hosmer--Lemeshow) chi-squared *p*-value = 0.119. CI = confidence interval; SAPS 3 = Simplified Acute Physiology Score (SAPS) 3.

###### 

Logistic regression for prediction of hospital mortality (SAPS 3 + NT-pro-BNP)

                    **Odds ratio**   **95% CI**   ***p*-value**
  ---------------- ---------------- ------------ ---------------
  SAPS 3 score           1.09        1.08-1.11      \< 0.001
  ln~NT-pro-BNP~         1.13        1.05-1.21        0.001

Goodness of fit (Hosmer--Lemeshow) chi-squared *p*-value = 0.146. Natural-log-transformed (ln) NT-pro-BNP was used as the continuous variable.

CI = confidence interval; SAPS 3 = Simplified Acute Physiology Score (SAPS) 3.

Discussion
==========

In the present study, we showed that the serum level of NT-pro-BNP on admission has weak prognostic power and little additive prognostic power when combined with SAPS 3 score. Although previous studies \[[@B7]-[@B10]\] have shown that the NT-pro-BNP level can be a prognostic factor in critically ill patients, the present study represents the largest scale study.

In the present study, the serum NT-pro-BNP level on admission was significantly higher in ICU nonsurvivors than in survivors. Moreover, the mortality progressively increased with increasing levels of NT-pro-BNP. Our findings are compatible with previous reports. All four studies \[[@B7]-[@B10]\] consistently showed similar results.

Compared with previous studies, the prognostic power of NT-pro-BNP was similar or somewhat weaker. Almog *et al*. \[[@B7]\] showed that the area under the ROC curve of NT-pro-BNP levels for prediction of mortality was 0.75 (95% CI, 0.62--0.88). Meyer *et al*. \[[@B8]\] showed that the area under the ROC curve was 0.70 (95% CI, 0.64--0.77). In the present study, the area under the ROC curve was 0.67 (95% CI, 0.64--0.70). The reason for the lower prognostic power in the present study is unknown. To address this issue, additional validation of the prognostic power of NT-pro-BNP is needed. One possible explanation is that the population enrolled in the two previous studies may have been biased. Thus, the prognostic power of NT-pro-BNP might be overestimated. In the study by Almog and colleagues \[[@B7]\], the number of patients analyzed was only 78, and all were admitted to the medical ICU in a single center. In the study by Meyer and colleagues \[[@B8]\], 289 patients in only a single center were evaluated. Although Meyer *et al*. \[[@B8]\] included the entire spectrum of medical patients with a critical illness, many had cardiac disease because the ICU in that study was in the Department of Cardiology. In those patients, the NT-pro-BNP level was more likely to have prognostic power. Compared with the previous two studies, a much larger number of number of patients were enrolled in the present study (n = 1440), and they were admitted not only to the medical ICU but also to the surgical ICU at multiple centers. Single measurement of the NT-pro-BNP level on admission can be an attractive prognostic factor if it is sufficiently powerful because other scoring systems, such as the SAPS 3, are somewhat complex and time consuming. Unfortunately, our data suggest that the NT-pro-BNP level alone is not a powerful prognostic factor in patients admitted to the ICU.

Along with its weak power for prediction of mortality, our data suggest that the NT-pro-BNP level plays little adjunct role when combined with SAPS 3 score. This result is not compatible with previous reports. Meyer *et al*. \[[@B8]\] showed that the SAPS 2 score and the NT-pro-BNP level were independently associated with hospital survival in a logistic regression model. Kotanidou *et al*. \[[@B9]\] reported that the Acute Physiology and Chronic Health Evaluation (APACHE) II score and NT-pro-BNP level were independent predictors of mortality in multiple logistic regression analysis. The reason for the NT-pro-BNP level having little adjunct role in this study when combined with SAPS 3 is unknown. One possible explanation is that, in the present study, the NT-pro-BNP level was well correlated with many clinical parameters that are components of SAPS 3. Thus, prognosis may be already predicted enough by only SAPS 3 score.

In the present study, when combined with the SAPS 3 score, the AUC was increased little. As shown in Tables [3](#T3){ref-type="table"}, many clinical parameters and characteristics were overlapped by the SAPS 3 score and NT-pro-BNP level. Thus, when analyzed using the combination of the SAPS 3 and NT-pro-BNP level, the power of NT-pro-BNP was offset. For example, renal complication is the reason whose level of NT-pro-BNP is highest among the reason of ICU admission (Figure [3](#F3){ref-type="fig"}). This suggests that the prognostic power of NT-pro-BNP is due partly to the poor prognosis of renal failure patients. However, blood urea nitrogen, creatinine, pH, HCO~3~^-^, and urine output are components of the SAPS 3 score. The NT-pro-BNP level was also well correlated with these parameters, which are important prognostic factors in patients with renal failure. The poor prognosis of renal failure is already sufficiently predicted by the SAPS3 score. Thus, NT-pro-BNP had only a limited effect upon combination with the SAPS 3 score.

Conversely to usual biomarkers, severity score have been proven to be poorly calibrated to predict individual mortality. This may be because of differences in the patient case-mix or changing medical practice over time \[[@B11]\]. For example, SAPS 3 score showed mixed result in the external validation studies \[[@B12]-[@B17]\]. In this study, this phenomenon was also observed. Although SAPS 3 score was independent predictor for mortality, the area under the ROC curve was only 0.83. For NT-pro-BNP, there has been also variability for the power to predict mortality in previous studies. Thus, further validation study for NT-pro-BNP is mandatory.

The limitation of this study is potential selection bias. In this study, there were no definite criteria for the measurement of NT-pro-BNP. Basically, this study was multicenter observational study. Thus, in some centers, NT-pro-BNP was measured routinely for all patients, while in other centers, NT-pro-BNP was measured by clinician's preference. Thus, selection bias for enrollment of patients may exist. However, the level of NT-pro-BNP was variable, which suggests that patients who were unlikely to have cardiac disease were also enrolled. Baseline characteristics also showed that the percentage of ischemic heart disease or heart failure was not high (11.1 and 7.5%, respectively), which supports selection bias for patients with cardiac disease was unlikely to occur.

The present study is valuable in that it was of a multicenter, prospective design. In the present study, multiple ICU settings (medical or surgical or multidisciplinary) in multiple centers were analyzed. Thus, the enrolled population may be representative of real-world ICU patients. To be a good prognostic marker, NT-pro-BNP should be validated in a large-scale multicenter study. Our results provide valuable information regarding the limited role of NT-pro-BNP in general ICU patients. Further investigation of the role of NT-pro-BNP in critically ill patients with various clinical characteristics is needed.

Conclusions
===========

In conclusion, the NT-pro-BNP level was more elevated in nonsurvivors in a multicenter cohort of critically ill patients. However, there was little additional prognostic power when adding NT-pro-BNP to SAPS 3 score. Further investigation of NT-pro-BNP as a prognostic factor in patients admitted to the ICU is needed.
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